Physician profile
Ryan B Tuttle
NPI 1730471681
$723.41
in general payments reported to CMS, 2019-2025
19 companies · $20.41 in 2025
The $20.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.55 · 2020: $73.66 · 2021: $234 · 2022: $149 · 2023: $105 · 2024: $58.86 · 2025: $20.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $116.30 | 2021 | |
| Novo Nordisk INC | $107.00 | 2020-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $69.22 | 2022-2024 | Vraylar |
| Astellas Pharma US INC | $64.04 | 2019-2020 | |
| Exact Sciences Corporation | $51.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $47.57 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $36.59 | 2022-2023 | Eliquis |
| Dexcom, INC. | $30.06 | 2022-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $28.67 | 2022-2023 | Arexvy |
| Amgen INC. | $27.82 | 2021-2023 | Otezla, Repatha |
| Supernus Pharmaceuticals, INC. | $21.64 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.44 | 2021 | |
| Genentech USA, INC. | $15.23 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.13 | 2020 | |
| Abbott Laboratories | $14.96 | 2021 | |
| Amarin Pharma, INC. | $12.30 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Tuttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.